MedTrace Logo

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

NCT07511543 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 826

Last updated 2026-07-21

No results posted yet for this study

Summary

Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin.

The investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a vanguard phase of 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. Once complete the full-scale phase III study of 826 patients (including 100 patients from the vanguard phase) at 52 global stroke centers will start.

These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. During the vanguard phase, the investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The full trial will establish the benefit of semaglutide to improve the outcomes of patients with LVO treated with EVT.

Conditions

Interventions

DRUG

Semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Aristeidis Katsanos, MD · Population Health Research Institute

  • Mike Sharma, MD · Population Health Research Institute

  • Ashkan Shoamanesh, MD · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2031-09-30
Completion
2031-12-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07511543 on ClinicalTrials.gov